AbbVie reports positive results from Phase III HCV drug trial in Japan

9 January 2017

AbbVie (NYSE: ABBV) has released top-line results from an eight week Phase III study into its investigational glecaprevir/pibrentasvir regimen (ABT-493 / ABT-530) against hepatitis C.

The study adds to similar findings from a parallel global study, published in November 2016. The Japanese results are important as regulators there require data generated on the domestic market to be included in marketing applications.

The outcome will raise expectations that the American pharma giant would receive a positive decision following submission of a New Drug Application to the Japanese Ministry of Health, Labour and Welfare.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK